Electra Therapeutics Raises $183M to Propel Precision Cancer Therapies Globally

Editorial Team

Last updated 24-10-2025

2 min

Electra Therapeutics secured $183 million in Series C funding to advance immune and cancer therapies.

Major investors include EQT Life Sciences, Nextech Invest, Mubadala Capital, Sanofi, and HBM Healthcare Investments AG.

The funding supports Electra’s clinical study of ELA026 for secondary haemophagocytic lymphohistiocytosis (sHLH).

Electra plans to expand into blood cancers and boost its ELA822 candidate for immune conditions.

The investment highlights global collaboration in biotech, mixing capital, science, and determination.

Electra Therapeutics, a US-based biotech player, has just wrapped up a hefty $183 million Series C funding round – and yes, that’s quite the confidence boost in today’s investment climate. The round was led by EQT Life Sciences and Nextech Invest, with heavyweight backers like Mubadala Capital, Sanofi, and HBM Healthcare Investments AG all jumping in for good measure.

Specialising in immune and cancer therapies, Electra has built its reputation around what’s called “precision medicine” – basically, designing drugs that zero in on overactive immune cells while leaving healthy ones to get on with their job. I’ve always found this idea fascinating; it feels spot on for where biotech is heading, with fewer blanket treatments and more tailored approaches.

The new funding will push forward a global clinical study of Electra’s lead programme, ELA026, aimed at tackling secondary haemophagocytic lymphohistiocytosis – or sHLH, which, to keep things simple, is a rare but severe immune disorder. On top of that, the company plans to widen the programme’s scope to cover blood cancers and give a boost to another pipeline candidate, ELA822, exploring immune and inflammatory conditions.

To me, what’s interesting is how investors from such different corners – from Abu Dhabi’s Mubadala Capital to France’s Sanofi – are backing a common vision. It’s a bit of a reminder that innovation doesn’t happen in silos anymore; capital, science, and grit are all crossing borders.

At Arageek, we often meet founders trying to bridge early science with market reality. Seeing ventures like Electra getting this kind of traction is encouraging – proof that perseverance, coupled with precise science, can still move mountains. I reckon that’s the kind of story every startup in MENA can draw a line from; because even if biotech feels another world away, the hustle’s universal.

🚀 Got exciting news to share?

If you're a startup founder, VC, or PR agency with big updates—funding rounds, product launches 📢, or company milestones 🎉 — AraGeek English wants to hear from you!